Clinical Trial Search

Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…

Primary: Oxygen Consumption (ml/kg/Min) — 14.82; 16.75; 28.77 ml/kg/min

Primary: Congruent Trial (Hearts) Accuracy — 87.96; 87.50 percentage of correct

Primary: Mean Change From Baseline to TC 1, Week 6 in MAS Score in the TC 1 PTMG — -1.5; -1.9; -2.2 score on a scale — p=0.0118

Primary: Safety and Tolerability of Dalfampridine-ER 10mg in Subjects With Cerebral Palsy (CP) — 1; 2; 6; 9 participants

Primary: Change in Walk Dynamic Motor Control Index 6-months After Orthopaedic Surgery — -2.4 normalized z-score

Primary: Change in MAS Score in the Gastrocnemius-soleus Complex (GSC) at the Ankle Joint of the (Most) Affected Lower Limb — -0.86; -0.97; -0.48 units on a scale — p=0.0029

Primary: Change in Gross Motor Function Measure (GMFM-66) During Treatment Phase — 2.2; 3.5 units on a scale

Primary: Change From Baseline in the Ashworth Scale (AS) Score of Plantar Flexors of the Primary Body Side at Day 29 (Week 4) of the First Injection Cycle (1st IC) — -0.7; -0.66…

Primary: MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 — -0.93; -1.15; -0.96; -1.02 Unit on a scale — p== 0.017

Primary: Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle — 53; 44; 26; 31 participants

Primary: Change in Walking Performance High Versus Low Frequency SBLTT Groups — 1872; 1551 strides per day — p=.39

Primary: Change in Quality of Upper Extremity Skills Test (QUEST) Score - Section on Dissociated Movements — 3.5 units on a scale

Primary: Change in Assisting Hand Assessment (AHA) — 6.4; 8; 5.5; 7.6 score on a scale

Primary: Bone Structure — 10.4; 7.6; 6.7; 9.0 percent change

Primary: Gait Metric Accuracy — 2.01 percentage of error

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Reported in the Double Blind (DB) + Open Label (OL) Period. — 177; 5; 91; 151 participants

Primary: Change in Motor Evoked Potential Amplitude — 12.4; 81.7; -34.4 percent change

Primary: Change in Cosine Similarity of the Muscle Synergies of the Most Affected Lower Limb — 2 percentage of muscle synergies

Primary: Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test — 0.83; 0.00; 0.50; -0.05 score on a scale

Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale

Primary: Unit on Gross Motor Function Measure Scale (GMFM) — 5.12; 2.00 units on a scale — p=0.007

Primary: Change in Affected Arm Movement Control — 74.9; 78.3; 83.8 percentage

Primary: Gaitmat Stance Measurements (AUC) — 4.48; 10.8; 20.9; 2.8 Root Mean Square of Velocity*Minutes

Primary: Cortical Excitability MEP Amplitude (µV) — 325 µV

Primary: Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended) — -0.6; -0.8; -0.5 units on a scale…

Primary: Change in Assisting Hands Assessment Logit Score at End of Treatment — 2.63; 4.33 Scores on a scale

Primary: Jebsen Taylor Hand Function Test for Dominant Hand — 130.1; 115.2 seconds

Primary: Change in Manual Dexterity — 10.7; 12.4; 14.4 points on assessment — p=0.03

Primary: Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 140; 97; 47; 21 participants